| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1994;58:811-814
© 1994 The Society of Thoracic Surgeons
Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France
Accepted for publication January 24, 1994.
* Address reprint requests to Dr Regnard, Centre Chirurgical Marie Lannelongue, 133 Avenue de la Résistance, 92350 Le Plessis Robinson, France.
The aim of this study was to evaluate the prognostic significance of elevated preoperative carcinoembryonic antigen (CEA) levels in cases of resected primary lung cancer. Between 1985 and 1989, 152 patients with tumors and CEA levels above 10 ng/mL underwent operation. One hundred twenty-five of them underwent resection of their tumors and the other 27 underwent exploratory thoracotomy only. Fifty-two percent of cancers were adenocarcinomas and 33% were epidermoid. Forty-two resected tumors were classified as stage I, 29 as stage II, 45 as stage IlIa, 7 as stage IIIb, and 2 as stage IV. The 3-year actuarial survival rate was 54% for patients with stage I tumors, 28% for those with stage II, 18% for those with stage IIIa, 44% for those with stage IIIb, and 0% for those with stage IV tumors. The 5 year actuarial survival was 40% for those with stage I tumors, 28% for those with stage II, 7% for those with stage IlIa, and 0% for those with stage IIIb tumors. Preoperative CEA levels increased from stage I to stage IlIa (p < 0.05). However, based on preoperative CEA levels we were not able to predict resectabiliry, because levels were not significantly different between stage IlIa and exploratory thoracotomy-only groups. Adenocarcinoma was not significantly associated with higher CEA levels than was epidermoid, except in stage IlIa disease (p < 0.05). We found a critical unfavorable level of prognostic significance at 30 ng/mL. Within patients who underwent resection of stage I or II tumors, those with preoperative CEA levels under 30 ng/mL demonstrated significantly prolonged survival over those with CEA above 30 ng/mL (p < 0.05). Virtually all patients with marked elevations of CEA levels (>50 ng/mL) died within 2 years. Therefore, these patients must be highly suspected of having metastases even if operative staging may appear limited. Determining preoperative CEA levels provides prognosis information which may supplement that available by staging.
This article has been cited by other articles:
|
|
 |
|
  M. TOMITA, T. SHIMIZU, T. AYABE, A. YONEI, and T. ONITSUKA Prognostic Significance of Tumour Marker Index Based on Preoperative CEA and CYFRA 21-1 in Non-small Cell Lung Cancer Anticancer Res, July 1, 2010; 30(7): 3099 - 3102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Matsuoka, S. Sumitomo, N. Nakashima, D. Nakajima, and N. Misaki Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer Eur J Cardiothorac Surg, September 1, 2007; 32(3): 435 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fukai, Y. Sakao, M. Sakuraba, S. Oh, K. Shiomi, S. Sonobe, Y. Saitoh, and H. Miyamoto The prognostic value of carcinoembryonic antigen in T1N1M0 and T2N1M0 non-small cell carcinoma of the lung Eur J Cardiothorac Surg, September 1, 2007; 32(3): 440 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-H. Hsu, C.-S. Huang, H.-S. Hsu, W.-J. Huang, H.-C. Lee, B.-S. Huang, and M.-H. Huang Preoperative Serum Carcinoembryonic Antigen Level is a Prognostic Factor in Women With Early Non-Small-Cell Lung Cancer Ann. Thorac. Surg., February 1, 2007; 83(2): 419 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tomita, T. Shimizu, Y. Matsuzaki, M. Hara, T. Ayabe, and T. Onitsuka Prognostic Significance of Carcinoembryonic Antigen Level in Pleural Lavage Fluid for Patients With Lung Adenocarcinoma Ann. Thorac. Surg., July 1, 2005; 80(1): 276 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Okada, W. Nishio, T. Sakamoto, K. Uchino, T. Yuki, A. Nakagawa, and N. Tsubota Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease Ann. Thorac. Surg., July 1, 2004; 78(1): 216 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sawabata, H. Hirano, M. Inoue, Y. Okumura, H. Asada, S.-i. Takeda, and H. Maeda Immunohistochemical analysis of resectedclinical Stage I pulmonary adenocarcinomas withhigh preoperative levels of serumcarcinoembryonic antigen Ann. Thorac. Surg., July 1, 2003; 76(1): 203 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sawabata, M. Ohta, S.-i. Takeda, H. Hirano, Y. Okumura, H. Asada, and H. Maeda Serum carcinoembryonic antigen level in surgically resected clinical stage i patients with non-small cell lung cancer Ann. Thorac. Surg., July 1, 2002; 74(1): 174 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Suzuki, K. Nagai, J. Yoshida, E. Moriyama, M. Nishimura, K. Takahashi, and Y. Nishiwaki Prognostic factors in clinical stage I non-small cell lung cancer Ann. Thorac. Surg., April 1, 1999; 67(4): 927 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Rubins, J. Dunitz, H. B. Rubins, M. A. Maddaus, and D. E. Niewoehner Serum carcinoembryonic antigen as an adjunct to preoperative stagingof lung cancer J. Thorac. Cardiovasc. Surg., September 1, 1998; 116(3): 412 - 416. [Abstract] [Full Text]
|
|
|
|
|
|
J. F. Vansteenkiste, P. R. De Leyn, G. J. Deneffe, G. Stalpaert, K. L. Nackaerts, T. E. Lerut, and M. G. Demedts Survival and Prognostic Factors in Resected N2 Non-Small Cell Lung Cancer: A Study of 140 Cases Ann. Thorac. Surg., May 1, 1997; 63(5): 1441 - 1450. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
